Nyxoah Q4 Earnings Call Highlights

As of Dec. 31, 2025, Taelman said Nyxoah’s team was focused on 125 of the top 400 U.S. accounts. Within that group, the company trained 145 surgeons across 125 high-volume accounts. Nyxoah completed 120 Value Analysis Committee (VAC) submissions and had received 57 VAC approvals by quarter-end, with “no VAC rejections to date,” he said.Nyxoah received U.S. FDA approval for Genio on Aug. 8, 2025 and began actively launching the product, with “first implants and revenue as early as September 2025,” according ...